The Impact of rs767455 and rs1061622 Polymorphisms ‎on ‎Treatment Outcomes in Iraqi Ankylosing Spondylitis ‎Patients Taking ‎Etanercept

Document Type : Original Article

Authors

Abstract

Background: Ankylosing spondylitis (AS) is inflammation of the sacroiliac joints and ‎spine, associated with clinical symptoms such as pain and stiffness in ‎the vertebral column, after which, in a considerable number of ‎individuals, new bone growth occurs.
Objective: The current research study attempted to find out whether the ‎presence of SNPs in TNF receptor [TNFRSF1A ‎‎(rs767455), TNFRSF1B‎‎ (rs1061622)] encoding genes could influence ‎patients' outcomes to etanercept in a specimen of Iraqi AS patients.
Patients and methods: Sixty patients with established AS receiving only etanercept were selected to be enrolled in this research with a mean age of 40.75 ± 8.67 years, 51 patients of them were males and only 9 patients were females. Patients were classed as "responders" if just obtained a BASDAI 50 clinical response and as "non-responders" if they can't achieve a BASDAI 50 clinical elaboration after at least 6 months treatment. After PCR products amplification of purified blood DNA, TNF receptor (TNFRSF1A and TNFRSF1B‎‎) genes SNPs were established by Sanger sequencing.
Results: The analysis of this study expressed that there was a significant ‎incidence of TT genotype of rs1061622 (P = 0.022) in responder ‎group, whereas the TG genotype of the same SNP was considerably ‎present in the group that did not respond (P = 0.002). Finally, a ‎non-significant difference existed in alleles and genotypes frequency ‎between responder and non-responder groups of rs767455 SNP ‎in TNFRSF1A gene.
Conclusions: The wild TT genotype of rs1061622 predicts etanercept responsiveness in ankylosing spondylitis patients. The TG genotype of the same SNP increases the probability of non-responding.
 

Keywords